These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29325229)

  • 1. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
    El Rashedy AA; Olotu FA; Soliman MES
    Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket binders.
    Radi M; Schenone S; Botta M
    Curr Pharm Biotechnol; 2013; 14(5):477-87. PubMed ID: 22429131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
    Park H; Hong S; Kim J; Hong S
    J Am Chem Soc; 2013 Jun; 135(22):8227-37. PubMed ID: 23679864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
    Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
    J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
    Roskoski R
    Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
    Zhan JY; Ma J; Zheng QC
    J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
    Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
    Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
    Cao R; Wang Y; Huang N
    J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
    Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
    J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.